

β -Adrenergic Upregulation of the $\text{Na}^+\text{-K}^+\text{-2Cl}^-$ Cotransporter in Rat Parotid Acinar Cells

Marc Paulais and R. James Turner

Clinical Investigations and Patient Care Branch,

National Institute of Dental Research, National Institutes of Health, Bethesda, Maryland 20892

Abstract

We used the pH-sensitive fluorescent dye 2',7'-bis(2-carboxyethyl)-5(6')-carboxyfluorescein to monitor the recovery of the intracellular pH (pH_i) of rat parotid acini from an NH_4^+ -induced alkaline load. This recovery was markedly inhibited by the loop diuretic bumetanide and by Cl^- removal, indicating that it is largely due to NH_4^+ entry via the basolateral $\text{Na}^+\text{-K}^+\text{-2Cl}^-$ cotransporter. The rate of recovery of pH_i was enhanced threefold by pretreatment (37.5 s) with isoproterenol ($K_{1/2} = 21.5$ nM) or norepinephrine (in the presence of phentolamine), and blocked by the β_1 -specific antagonist atenolol, indicating an upregulation of cotransport activity by β_1 -adrenergic stimulation. The effect of isoproterenol was prevented by protein kinase inhibitors and mimicked by cAMP analogues, and by maneuvers known to increase cytosolic cAMP levels in these cells, consistent with the involvement of protein kinase A. Physiologically, such an upregulation of the acinar $\text{Na}^+\text{-K}^+\text{-2Cl}^-$ cotransporter would lead to an increase in acinar chloride uptake across the basolateral membrane, and consequently, an increase in overall chloride and fluid secretion. Prevention of this upregulation by β -blockers and possibly by other commonly used clinical agents may account for the dry mouth and dry eyes experienced by some patients taking these medications. (*J. Clin. Invest.* 1992; 89:1142–1147.) Key words: exocrine gland • fluid secretion • loop diuretic • chloride secretion • xerostomia

Introduction

$\text{Na}^+\text{-K}^+\text{-2Cl}^-$ cotransporters are found in a wide variety of cell types (1, 2). This transport system is thought to play a central role in salt and water movements in many absorptive and secretory epithelia. It is also involved in volume regulatory phenomena in both epithelial and nonepithelial cells. As is characteristic of other transporters that are extensively utilized in nature, $\text{Na}^+\text{-K}^+\text{-2Cl}^-$ cotransport activity is regulated in a very tissue-specific manner (1, 2). Thus, in some cell types, increases in cyclic nucleotide levels, intracellular calcium concentration, or protein kinase C activity stimulate the cotransporter, whereas in others, these same agents may have exactly the opposite effect, or possibly no effect at all. At present, the significance of these tissue specific differences remains largely unex-

plored; however, it is clear that these observations raise interesting questions related to the mechanisms involved in the regulation of this important transporter at both the whole cell and individual protein level.

Studies from a number of laboratories, including our own, indicate that a $\text{Na}^+\text{-K}^+\text{-2Cl}^-$ cotransporter is responsible for driving the bulk of the acinar chloride secretion associated with fluid production in salivary glands (3–7). This process is thought to conform to the following scheme (8, 9). The $\text{Na}^+\text{-K}^+\text{-2Cl}^-$ cotransporter concentrates Cl^- above electrochemical equilibrium in the acinar cytoplasm, using the extracellular to intracellular sodium gradient generated by Na^+/K^+ ATPase. Stimulation by secretagogues raises intracellular calcium levels, causing the opening of basolateral Ca^{2+} -activated K^+ channels and (putative) apical Ca^{2+} -activated Cl^- channels. This allows K^+ and Cl^- to flow out of the cell down their respective electrochemical gradients, Cl^- into the lumen, and K^+ into the interstitium. Na^+ then follows Cl^- paracellularly to preserve electroneutrality, and water follows NaCl into the lumen osmotically.

In some tissues, the $\text{Na}^+\text{-K}^+\text{-2Cl}^-$ cotransporter is quiescent in resting cells; however, this is not the case in salivary glands (10). Thus, the above model does not necessarily require upregulation of cotransporter activity by secretagogues (although such an upregulation would enhance transepithelial Cl^- movement, and thus fluid secretion). Nevertheless, several observations indicated to us that the cotransporter might be regulated by certain agonists. When $^{36}\text{Cl}^-$ -loaded rat parotid or submandibular acini are stimulated with maximal doses of muscarinic (Ca^{2+} mobilizing) agonists they undergo an initial rapid ($t_{1/2} < 10$ s) and dramatic (30–50%) loss of intracellular Cl^- (via the apical Cl^- channel), followed by a partial recovery to intracellular Cl^- levels significantly below resting values (4, 7, 11). In HCO_3^- -free medium, this recovery is essentially completely blocked by the loop diuretics bumetanide and furosemide, indicating that it is due to Cl^- entry via the $\text{Na}^+\text{-K}^+\text{-2Cl}^-$ cotransporter (4, 7). This recovery coincides with the transition between the initial and the sustained phases of fluid secretion, and presumably reflects the adjustment of the cells to a new steady state characteristic of a continuous secretory response. When the same experiments were carried out with the combined α -adrenergic (Ca^{2+} mobilizing) and β -adrenergic (cAMP generating) agonist epinephrine, a similar pattern of $^{36}\text{Cl}^-$ loss and recovery was seen. However, in contrast to the sustained decrease in Cl^- content observed with muscarinic agonists, in this case, acini were observed to recover to near resting intracellular Cl^- levels (11, 12). Interestingly, this enhanced recovery of Cl^- content was blocked by the β -adrenergic antagonist propranolol (11). In additional experiments it was found that stimulation of both rat submandibular (13) and rat parotid (J. E. Melvin and R. J. Turner, unpublished observations) acini with the β -adrenergic agonist isoproterenol caused a gradual in-

Address correspondence and reprint requests to Dr. R. James Turner, Bldg. 10, Rm. 1A06, National Institutes of Health, Bethesda, MD 20892.

Received for publication 03 June 1991 and in revised form 16 December 1991.

The Journal of Clinical Investigation, Inc.
Volume 89, April 1992, 1142–1147

crease in $^{36}\text{Cl}^-$ content that was prevented by furosemide (13). These results are suggestive of an upregulation of the acinar $\text{Na}^+\text{-K}^+\text{-2Cl}^-$ cotransporter by β -adrenergic stimulation.

The purpose of the present study was to directly assess the effect of β -adrenergic stimulation on the $\text{Na}^+\text{-K}^+\text{-2Cl}^-$ cotransporter in rat parotid acini. In order to do so, we employed a novel method for monitoring cotransporter activity. Briefly stated, we have taken advantage of the fact that NH_4^+ can substitute for K^+ on the cotransporter (14–16). This made it possible for us to follow cotransporter activity via the changes in intracellular pH associated with cotransporter-mediated dissipation of NH_4^+ gradients. We demonstrate here that the acinar $\text{Na}^+\text{-K}^+\text{-2Cl}^-$ cotransporter is indeed upregulated by β -adrenergic stimulation, apparently via a cyclic AMP/protein kinase A-dependent pathway. Prevention of this upregulation by β -blockers, and possibly by other commonly used clinical agents, may account for the dry mouth (xerostomia) and dry eyes experienced by some patients taking these medications (17, 18).

Methods

Materials. Collagenase (type CLSPA) was obtained from Worthington Biomedical Corporation (Newark, NJ). (–)Isoproterenol, DL-propranolol, epinephrine, norepinephrine, atenolol, carbachol, phentolamine, ouabain, and IBMX¹ (3-isobutyl-1-methylxanthine) were from Sigma Chemical Co. (St. Louis, MO). 8-4 CPT cAMP (8-[4 chlorophenylthio]-adenosine 3',5'-cyclic monophosphate) and 8 Br cAMP (8-bromo adenosine 3',5'-cyclic monophosphate) were from Boehringer Mannheim Biochemicals (Indianapolis, IN) and bumetanide was a gift from Hoffmann-LaRoche Laboratories (Nutley, NJ). Forskolin, 1,9-dideoxyforskolin, K252a, H9, staurosporine, and BCECF/AM (2',7'-bis[2-carboxyethyl]-5[6']-carboxyfluorescein pentaacetoxymethyl ester) were from Calbiochem Corp. (San Diego, CA). BCECF/AM was stored at -20°C as a 2 mM stock solution in dimethyl sulfoxide.

Solutions. Experiments were typically carried out in a physiological salt solution (PSS) containing 135 mM NaCl, 5.8 mM KCl, 1.8 mM CaCl_2 , 0.8 mM MgSO_4 , 0.73 mM NaH_2PO_4 , 11 mM glucose, 20 mM Hepes, 2 mM glutamine, and 0.01% BSA. In Cl^- -free PSS, gluconate was used to replace chloride, and the ionic calcium activity of the medium was matched to that of PSS by adding additional calcium salts (19). In Ca^{2+} -free PSS, 0.1 mM EGTA was substituted for CaCl_2 . All solutions were titrated to pH 7.4 with NaOH.

Acinar preparation. Dispersed parotid acini were prepared from the parotid glands of two male, 250–350 g Wistar strain rats (Harlan Sprague-Dawley Inc., Indianapolis, IN) by collagenase digestion, as previously described (20), except that hyaluronidase was omitted from the digestion medium. Final parotid acinar preparations were washed and resuspended (5 ml/animal) in PSS, then rested for 10 min at 25°C before loading with BCECF (see below). Throughout this and the subsequent experimental period, the acini were kept continuously agitating (85 cycles/min in a shaking water bath) and gassed with 100% O_2 .

Intracellular pH measurements. Isolated acini were loaded with the pH-sensitive fluorescent dye BCECF by incubation with 2 μM of the membrane permeant species BCECF/AM for 30 min at 25°C . Intracellular BCECF fluorescence was monitored at 37°C in “ratio mode,” using a spectrofluorimeter (model 8000C; SLM Instrs. Inc., Urbana, IL) (20). The fluorescent signal was calibrated to yield intracellular pH (pH_i) values, as previously described (20).

1. **Abbreviations used in this paper:** BCECF, (2',7'-bis[2-carboxyethyl]-5[6']-carboxyfluorescein; BCECF/AM, BCECF pentaacetoxymethyl ester; 8Br cAMP, 8-bromo cAMP; 8-4 CPT cAMP, (8-[4 chlorophenylthio]-cAMP); IBMX, (3-isobutyl-1-methyl-xanthine); pH_i -intracellular pH; PSS, physiological salt solution.

Data analysis and presentation. Fluorescence traces were converted to numerical ASCII files, using software supplied with the 8000C spectrofluorimeter (SLM Instrs.), then transferred into the program Sigma-plot 4.0 (Jandel Sci., Corte Madera, CA) for conversion to pH_i values and analysis (see Results).

Each experimental value given in the figures or text is the mean \pm SEM for three or more independent determinations carried out under identical conditions on different acinar preparations. P values < 0.05 (Student's t test) were taken to represent statistically significant differences.

Results

Effect of bumetanide, isoproterenol, and other treatments on the recovery of rat parotid acinar cells from an NH_4^+ -induced acute alkaline load. The behavior of the pH_i of rat parotid acinar cells following the addition of 30 mM NH_4Cl to the extracellular medium is illustrated in the lower trace of Fig. 1 A. In this ‘control’ run (acini in PSS) the cells first rapidly alkalinize ($t_{1/2} < 3$ s, $\Delta\text{pH}_i = 0.32 \pm 0.01$; $n = 47$) then recover to a final pH_i (7.36 ± 0.01 ; $n = 47$) which is significantly below resting levels (7.56 ± 0.01 ; $n = 47$). This initial intracellular alkalization is a common result of NH_4^+ addition to cells, and is caused by the rapid equilibration of the membrane permeant species NH_3 and its intracellular combination with H^+ to form NH_4^+ . From this ΔpH_i in response to a 30 mM NH_4Cl challenge we calculate that the intrinsic buffering power (21), β_i , of these cells is 44.9 ± 1.4 mmol/liter per pH U.

Since most cells recover from an acute alkaline load via HCO_3^- -dependent mechanisms, and since our experiments were carried out in HCO_3^- -free medium (see Methods), one might expect a large part of the pH_i recovery observed after NH_4^+ -induced alkalization in Fig. 1 A to be due to dissipation




Figure 1. The effects of bumetanide, isoproterenol and NH_4^+ on the response of rat parotid acini to an acute alkaline load. The results shown in A and C are representative BCECF traces from rat parotid acini suspended in PSS and challenged with 30 mM NH_4Cl , at the times indicated (dilution 1%). In these experiments, acini were studied in the presence (upper trace) and absence (lower trace) of 0.1 mM bumetanide (bum; added 75 s before NH_4^+). In C, 3×10^{-8} M isoproterenol (iso) was added 37.5 s before NH_4Cl . The results shown in B and D are representative BCECF traces from acini which were preequilibrated (10 min) in PSS containing 30 mM sodium propionate, then centrifuged and diluted at time zero into propionate-free PSS containing no additions (B) or 3×10^{-8} M isoproterenol (D). An acute alkaline load is generated in these cells by the rapid diffusion of the permeant species propionic acid out of the cytoplasm.

of the extracellular to intracellular NH_4^+ gradient. In other words, the rate of pH_i recovery should be, at least in part, a measure of acinar membrane NH_4^+ permeability.

It has been shown that NH_4^+ can substitute for K^+ on the $\text{Na}^+-\text{K}^+-2\text{Cl}^-$ cotransporter in several tissues (14–16), including salivary glands (R. J. Turner and J. N. George, unpublished observations). We demonstrate in the upper trace of Fig. 1 *A* (+bum) that the pH_i recovery of rat parotid acinar cells is markedly slowed by 0.1 mM bumetanide, a well known inhibitor of this transporter (quantitation of these results is discussed below). In additional experiments (not shown) we have verified that SITS (1 mM), an inhibitor of Cl^-/OH^- exchange, has no significant effect on this recovery. Since the $\text{Na}^+-\text{K}^+-2\text{Cl}^-$ cotransporter is thought to be highly active in salivary tissue, these results suggest that a significant component of pH_i recovery following NH_4^+ -induced alkalinization of these cells occurs via NH_4^+ entry on this transport system. Further evidence for this hypothesis is provided in Fig. 1 *B*. Here we have alkalinized the acinar cells by propionate removal, rather than NH_4^+ addition (see Fig. 1, *legend*). The magnitude of the resulting initial alkalinization ($\Delta\text{pH}_i = 0.37 \pm 0.03$ above resting pH_i ; $n = 3$) is similar to that seen in Fig. 1 *A*, but the rate of pH_i recovery more closely resembles that seen in bumetanide-treated acini. This result suggests that the bumetanide-inhibitable component of pH_i recovery seen in Fig. 1 *A* is also NH_4^+ -dependent, consistent with the involvement of a bumetanide-sensitive NH_4^+ transport pathway.

The effect of preincubating (37.5 s) the acinar suspension with the β -adrenergic agonist isoproterenol (3×10^{-8} M) before NH_4^+ addition is illustrated in Fig. 1 *C*. Isoproterenol treatment dramatically accelerates the rate of pH_i recovery with little effect on the magnitude of the initial alkalinization ($\Delta\text{pH}_i = 0.29 \pm 0.01$; $n = 15$) or the value of the final pH_i (7.34 ± 0.01 ; $n = 15$). The acceleration of the rate of pH_i recovery produced by isoproterenol is blocked by propranolol (10^{-5} M; not shown) and dramatically inhibited by bumetanide (Fig. 1 *C*). No effect of isoproterenol on pH_i recovery is seen in cells alkalinized by propionate removal (Fig. 1 *D*).

The time courses of pH_i recovery illustrated in Fig. 1 conform well to a single exponential decay (not shown). Accordingly, we have used least-squares curve-fitting techniques to determine initial pH_i recovery rates, and thus quantitate our results. More specifically, we have fit our individual recovery traces to the equation

$$\text{pH}_i = (\text{pH}_{\text{initial}} - \text{pH}_{\text{final}})e^{-kt} + \text{pH}_{\text{final}} \quad (1)$$

where pH_i is the value of pH_i at time t , $\text{pH}_{\text{initial}}$ is the initial (alkaline) pH_i induced by the addition of NH_4^+ (at $t = 0$), pH_{final} is the final resting pH_i after NH_4^+ addition, and k is the recovery rate constant. In the least squares analyses $\text{pH}_{\text{initial}}$, pH_{final} and k were all treated as free parameters. The initial pH_i recovery rate is the slope of the pH_i vs. time curve ($d\text{pH}_i/dt$) at $t = 0$, which from equation (1) is given by $k(\text{pH}_{\text{initial}} - \text{pH}_{\text{final}})$. Under control conditions (30 mM NH_4Cl added to untreated acini in PSS) we find this initial recovery rate to be 0.31 ± 0.07 pH U/min ($n = 47$). This value can be converted to an initial NH_4^+ flux rate of 13.9 ± 3.1 mmol/min, using the value of β_i derived above.

Fig. 2 shows the combined results of a number of experiments performed as outlined in Fig. 1 and analyzed as just described. In each experiment, the initial rates of pH_i recovery




Figure 2. Effects of various treatments on the isoproterenol-induced enhancement of pH_i recovery from an acute alkaline load. The experimental procedures were as described for Fig. 1. Initial rates of pH_i recovery were calculated as described in the text. Rates have

been normalized to the initial rate obtained from a control run (30 mM NH_4Cl addition to untreated acini in PSS) carried out on the same preparation. Averaged normalized initial recovery rates from three or more independent experiments are shown in the presence (hatched bars) and absence (open bars) of isoproterenol (3×10^{-8} M), in the presence of bumetanide (bum, 0.1 mM), in Cl^- -free PSS (Cl free; all Cl^- replaced with gluconate and challenged with 15 mM $[\text{NH}_4]_2\text{SO}_4$), in the presence of 1 mM ouabain (ouab.) and in the absence of NH_4^+ (Na prop.; alkalinization by propionate removal as described in Fig. 1). In these experiments, ouabain was added 75 s before NH_4Cl (cf. Fig. 1) to minimize any dissipation of transmembrane ion gradients. *Initial recovery rates which are significantly different from control.

were normalized to the initial rate obtained from a control run (30 mM NH_4Cl addition to untreated acini in PSS) carried out on the same preparation. These results show clearly that the pH_i recovery from an NH_4^+ -induced alkaline load is strongly retarded by bumetanide, and that the enhancement of this recovery produced by isoproterenol is completely bumetanide inhibitable. These effects of bumetanide are duplicated by the removal of medium chloride (Fig. 2), a maneuver which would also result in suppression of $\text{Na}^+-\text{K}^+-2\text{Cl}^-$ cotransport activity (6). Furthermore, when the acinar cells are alkalinized by propionate removal rather than NH_4^+ addition, as in Fig. 1, *B* and *D*, pH_i recovery is significantly slower than that observed in the presence of NH_4^+ , and no effect of isoproterenol is seen (Fig. 2). Taken together, the above results provide strong evidence that the bumetanide inhibitable, NH_4^+ -dependent component of pH_i recovery illustrated in Fig. 1 is due to NH_4^+ entry via the $\text{Na}^+-\text{K}^+-2\text{Cl}^-$ cotransporter, and that the stimulation of this recovery induced by isoproterenol is due to an upregulation of cotransporter activity. Fig. 2 also shows that 1 mM ouabain has no effect on the stimulation of pH_i recovery induced by isoproterenol, indicating that this phenomenon is not due to upregulation of Na^+/K^+ ATPase and a concomitant change in driving forces for the cotransporter, or to NH_4^+ entry on the Na^+/K^+ ATPase itself.

The effect of isoproterenol concentration on the initial rate of pH_i recovery from an NH_4^+ -induced alkaline load is examined in Fig. 3. A half-maximal effect is observed at 2.15×10^{-8} M (see Fig. 3 legend). This value is close to, but somewhat lower than, typical $K_{1/2}$ values for isoproterenol-induced protein (amylase) secretion in this tissue ($\approx 10^{-7}$ M) (22–24).

Effects of intracellular cyclic AMP levels and protein kinase inhibitors. In parotid acinar cells, cAMP is thought to be the major intracellular messenger mediating the events associated with β -adrenoreceptor activation (25). In Fig. 4 *A* we illustrate that the permeant cAMP analogues 8 Br cAMP and 8-4 CPT cAMP mimic the effect of isoproterenol on pH_i recovery from an NH_4^+ -induced alkaline load. Simulation of recovery is also




Figure 3. Effect of isoproterenol concentration on the initial rate of pH_i recovery from an NH_4^+ -induced alkaline load. The experimental procedure was as described in Fig. 1 C, using the concentrations of isoproterenol indicated ($n \geq 3$ for all conditions). The line drawn through the points is a nonlinear least squares fit to the

data given by $K_{1/2} = 21.5 \pm 1.0$ nM, and a maximal initial pH_i recovery rate of 3.13 ± 0.02 times the control rate.

seen with forskolin (10^{-5} M), which increases intracellular cAMP levels by direct activation of the catalytic subunit of adenylate cyclase (24). The inactive forskolin analogue 1,9-di-deoxyforskolin was without effect. The phosphodiesterase inhibitor IBMX (10^{-4} M) also mimics the effect of isoproterenol, and has a marked synergistic effect when applied in combination with a submaximal dose of isoproterenol (3×10^{-9} M).

In Fig. 4 B we demonstrate that the stimulation of pH_i recovery induced by isoproterenol is blocked by the protein kinase inhibitors H9, staurosporin, and K252a. No significant effect of these compounds was observed on the recovery of untreated acini (data not shown). These results together with those shown in Fig. 4 A provide strong evidence that the upregulation of the $\text{Na}^+/\text{K}^+-2\text{Cl}^-$ cotransporter studied here is due to a phosphorylation event mediated by protein kinase A.

Effects of calcium. Several reports have suggested that changes in intracellular calcium concentrations may play some role in the response of rat parotid acinar cells to β -adrenergic agonists (26–28). Accordingly, we carried out experiments to explore the role of calcium, if any, in the effects studied here. In these experiments (Table I) we found that the isoproterenol-de-




Figure 4. Effects of intracellular cAMP levels (A) and protein kinase inhibitors (B) on the initial rate of pH_i recovery from an NH_4^+ -induced alkaline load. The experimental procedure was as described for Fig. 1 C ($n \geq 3$ for all conditions). 8-4 CPT cAMP ($8\text{-}4\text{ CPT}$; 2.5×10^{-3} M), 8-Br cAMP ($8\text{-}Br\text{ cAMP}$; 2.5×10^{-3} M), forskolin ($Forsk.$; 10^{-5} M), di-deoxyforskolin ($Dd\text{ Forsk.}$; 10^{-5} M), and isoproterenol (iso ; 3×10^{-9} M in A and 3×10^{-8} M in B) were added 37.5 s before NH_4Cl ,

IBMX (10^{-4} M) was added 75 s before NH_4Cl , and H9 (100 μM), staurosporine ($stauro.$; 1 μM), and K252a (20 μM) were added 20 min before NH_4Cl . *Initial recovery rates which are significantly different from control.

Table I. Effect of Calcium on the Isoproterenol-induced Enhancement of pH_i Recovery from an NH_4^+ -induced Alkaline Load*

Experimental condition	Initial recovery rate (experimental/control)		n
	–iso	+iso	
		10 nM	
PSS	1.0	1.63±0.10	16
EGTA	0.95±0.10	1.59±0.27	3
Carbachol pretreated	1.08±0.02	1.75±0.11	3

* Experiments were carried out as described in Fig. 1, A and C. ‘PSS’ denotes acini in PSS, ‘EGTA’ denotes acini in Ca^{2+} -free PSS (all calcium salts replaced with 0.1 mM EGTA) and ‘Carbachol pretreated’ denotes acini incubated in Ca^{2+} -free PSS containing 10^{-5} M carbachol for 10 min, then centrifuged and resuspended in Ca^{2+} -free PSS for the experiment. None of the recovery rates observed in the presence of isoproterenol (+iso) are significantly different from each other.

pendent stimulation of pH_i recovery from an NH_4^+ -induced alkaline load was not significantly affected by either the removal of extracellular calcium, or the depletion of intracellular IP_3 -sensitive calcium stores (accomplished by preincubation of acini with the Ca^{2+} mobilizing agonist carbachol in Ca^{2+} -free medium—see Table legend). These results argue strongly against a role for intracellular calcium concentration in the upregulation of the $\text{Na}^+/\text{K}^+-2\text{Cl}^-$ cotransporter studied here.

The effect of isoproterenol is mediated by the β_1 receptor. Isoproterenol is a combined β_1 and β_2 adrenergic agonist. We show in Fig. 5, however, that the effect of isoproterenol is mimicked by both epinephrine (a combined β_1 and β_2 agonist) and norepinephrine (a β_1 agonist), with approximately equal potency (experiments with epinephrine and norepinephrine were carried out in the presence of the α -adrenergic antagonist phenolamine to limit their effects to β -adrenergic receptors). We also demonstrate that the effect of isoproterenol is blocked by the β -adrenergic antagonist atenolol at a concentration (3×10^{-7} M) where it is highly specific for the β_1 receptor subtype (29). Thus, the effect of isoproterenol on the $\text{Na}^+/\text{K}^+-2\text{Cl}^-$ cotransporter appears to be mediated by β_1 adrenoreceptors.




Figure 5. Effects of β -adrenergic agonists and antagonists on the initial rate of pH_i recovery from an NH_4^+ -induced alkaline load. The experimental procedure was as described for Fig. 1 C ($n \geq 3$ for all conditions). Epinephrine (Epi ; 0.1 μM and 0.3 μM), norepinephrine

(NE ; 0.1 μM and 0.3 μM), and isoproterenol (iso ; 30 nM) were added 37.5 s before NH_4Cl , and atenolol (0.3 μM) was added 75 s before NH_4Cl . The effects of epinephrine and norepinephrine were assayed in the presence of 10^{-5} M phenolamine. *Initial recovery rates which are significantly different from control.

Discussion

We demonstrate here that the recovery of rat parotid acini from an NH_4^+ -induced acute alkaline load is dramatically enhanced by pretreatment with the β -adrenergic agonist isoproterenol (Fig. 1). This enhancement of pH_i recovery is completely inhibited by the loop diuretic bumetanide, and by chloride removal, and is absolutely dependent on the presence of NH_4^+ (Figs. 1 and 2). Taken together with the fact that NH_4^+ has been shown to share the $\text{Na}^+\text{-K}^+\text{-2Cl}^-$ cotransporter in several cell types (14–16), including salivary glands, these results provide strong evidence that this enhancement of pH_i recovery is due to increased NH_4^+ entry into the acinar cytoplasm via the cotransporter, and thus indicate that isoproterenol treatment results in an upregulation of cotransporter activity.

The effect of isoproterenol is mimicked by permeant cAMP analogues and forskolin, and is potentiated by the phosphodiesterase inhibitor IBMX (Fig. 4 A), indicating that it is associated with the increased intracellular cAMP levels known to occur following β -adrenergic stimulation of this tissue (24, 25, 30). The dose of isoproterenol yielding a half maximal effect on the cotransporter (2.15×10^{-8} M; Fig. 3) is in reasonable agreement with the half maximal effect of this agent on amylase secretion, a phenomenon which is also cAMP-mediated in the parotid (25, 31). Furthermore, since atenolol (a specific β_1 antagonist) blocks the effect of isoproterenol, and since both epinephrine (a combined β_1 and β_2 adrenergic agonist) and norepinephrine (a relatively specific β_1 agonist) mimic the effect of isoproterenol at comparable doses (Fig. 5), it appears that this upregulation, like amylase release (23, 30, 31), is mediated via the β_1 adrenoreceptor subtype (32). The fact that the effect of isoproterenol is blocked by the protein kinase inhibitors H9, staurosporine and K252a (Fig. 4 B) provides strong evidence that this effect is due to a phosphorylation event presumably mediated by protein kinase A.

As already mentioned, there is evidence for both up- and downregulation of $\text{Na}^+\text{-K}^+\text{-2Cl}^-$ cotransport activity in a variety of cell types (1, 2). In spite of the intense interest in this transporter, however, little has been established concerning the molecular mechanisms involved in these events. In addition, relatively few reports have distinguished between upregulation of cotransport activity which arises simply from changes in intracellular ion concentrations, and thus in thermodynamic driving forces for cotransport, and upregulation which arises from true changes in intrinsic transporter properties, resulting, for example, from direct modifications (e.g., phosphorylation) of the cotransporter or an associated regulatory protein.

A number of observations indicate that the effect of isoproterenol on the parotid $\text{Na}^+\text{-K}^+\text{-2Cl}^-$ cotransporter arises from a true modification of cotransport activity, rather than a secondary effect due to changes in ionic driving forces. In this regard, it is important to bear in mind that, in contrast to a number of other secretory tissues, fluid secretion in salivary glands arises primarily from Ca^{2+} mobilizing agonists, rather than cAMP generating agents such as isoproterenol (9). Thus, whereas muscarinic and α -adrenergic stimulation of salivary acini (Ca^{2+} mobilizing agents) result in a significant decrease in intracellular chloride content, which is associated with the fluid secretory response (4, 7, 11), stimulation with isoproterenol (10^{-5} M) results in no initial change in intracellular chloride, followed by a slow increase in chloride content (20–30%) which is first detectable after ~ 2 min of stimulation (13) (J. E. Melvin and

R. J. Turner, unpublished observations). As already mentioned, this latter effect has been shown to be blocked by furosemide in rat submandibular acini (13), and thus is almost certainly secondary to activation of the $\text{Na}^+\text{-K}^+\text{-2Cl}^-$ cotransporter. A small component of calcium mobilization from IP_3 -sensitive stores has, however, been observed in rat parotid acini in response to relatively large doses ($\geq 5 \mu\text{M}$) of isoproterenol (26–28). This phenomenon may be responsible for the small component of fluid secretion associated with β -adrenergic stimulation of intact perfused salivary glands by similar concentrations of this agonist (33). Although these effects occur at concentrations of isoproterenol several orders of magnitude greater than those relevant to the phenomenon studied here, we have nevertheless verified that the effect of isoproterenol we observe is still seen after depletion of IP_3 -sensitive Ca^{2+} stores (Table I). We have also verified that the activation of cotransporter activity is not secondary to an increased driving force for sodium generated by $\text{Na}^+\text{-K}^+$ ATPase (Fig. 2). All of these results argue strongly in favor of a true change in intrinsic cotransport properties induced by β -adrenergic stimulation.

Further studies will be required to characterize the molecular events involved in the upregulation of the cotransporter. In this regard, Pewett et al. (34) have recently demonstrated that an $M_r \sim 150,000$ protein thought to represent part or all of the $\text{Na}^+\text{-K}^+\text{-2Cl}^-$ cotransporter in the avian erythrocyte is a phosphoprotein. Although no correlation between cotransport activity and phosphorylation of this protein has yet been established, this result supports the conjecture that phosphorylation and dephosphorylation of the cotransporter itself may be involved in its regulation.

In vivo salivary glands typically receive simultaneous muscarinic, α -adrenergic, and β -adrenergic stimulation. Thus one would expect upregulation of the $\text{Na}^+\text{-K}^+\text{-2Cl}^-$ cotransporter to accompany the fluid secretory response. Physiologically, upregulation of the parotid $\text{Na}^+\text{-K}^+\text{-2Cl}^-$ cotransporter would lead to an increase in acinar chloride uptake across the basolateral membrane, and consequently, an increase in overall chloride and fluid secretion by the acinar cell (see Introduction). Larsson and Olgart (35) have, in fact, recently demonstrated that agents that increase intracellular cAMP levels in the rat parotid do indeed markedly enhance carbachol-induced salivary secretion (100–250%) consistent with this scheme. Whether similar effects occur in human salivary tissues remains to be determined. However, it is often reported that many commonly used drugs result in complaints (17, 18) of dry mouth (xerostomia) and/or dry eyes, the underlying causes of which, in many cases, are unknown. Among these drugs are a number of β -blockers (17, 18) that could produce these side effects by preventing the upregulation of the $\text{Na}^+\text{-K}^+\text{-2Cl}^-$ cotransporter characterized here. Indeed, any drug that interfered with the β -receptor/cAMP/protein kinase A cascade might produce such symptoms. From the perspective of symptomatic treatment of these exocrine disorders (e.g., Sjögren's syndrome; reference 36), the results presented here suggest that a therapy combining both Ca^{2+} -mobilizing and cAMP-generating stimuli would be most effective.

Acknowledgments

We wish to thank Drs. Bruce J. Baum, Philip C. Fox, and Mark A. Knepper for advice and encouragement during the course of this work. We also thank Ms. Janet N. George for excellent technical assistance.

References

- O'Grady, S. M., H. C. Palfrey, and M. Field. 1987. Characteristics and functions of Na-K-Cl cotransport in epithelial tissues. *Am. J. Physiol.* 253:C177-C192.
- Haas, M. 1989. Properties and diversity of (Na-K-Cl) cotransporters. *Annu. Rev. Physiol.* 51:443-457.
- Martinez, J. R., and N. Cassity. 1985. Cl^- requirement for saliva secretion in the isolated, perfused rat submandibular gland. *Am. J. Physiol.* 249:G464-G469.
- Nauntofte, B., and J. H. Poulsen. 1986. Effects of Ca^{2+} and furosemide on Cl^- transport and O_2 uptake in rat parotid acini. *Am. J. Physiol.* 251:C175-C185.
- Novak, I., and J. A. Young. 1986. Two independent anion transport systems in rabbit mandibular salivary glands. *Pfluegers Arch. Eur. J. Physiol.* 407:649-656.
- Turner, R. J., J. N. George, and B. J. Baum. 1986. Evidence for a $\text{Na}^+/\text{K}^+/\text{Cl}^-$ cotransport system in basolateral membrane vesicles from the rabbit parotid. *J. Membr. Biol.* 94:143-152.
- Melvin, J. E., M. Kawaguchi, B. J. Baum, and R. J. Turner. 1987. A muscarinic agonist-stimulated chloride efflux pathway is associated with fluid secretion in rat parotid acinar cells. *Biochem. Biophys. Res. Commun.* 145:754-759.
- Silva, P., J. Stoff, M. Field, L. Fine, J. N. Forrest, and F. H. Epstein. 1977. Mechanism of active chloride secretion by shark rectal gland: Role of Na-K-ATPase in chloride transport. *Am. J. Physiol.* 233:F298-F306.
- Petersen, O. H., and Y. Maruyama. 1984. Calcium-activated potassium channels and their role in secretion. *Nature (Lond.)* 307:693-696.
- Kawaguchi, M., R. J. Turner, and B. J. Baum. 1986. Cl^- and Rb^+ uptake in rat parotid acinar cells. *Arch. Oral Biol.* 31:679-683.
- Martinez, J. R., and P. Reed. 1988. Effect of α -receptor stimulation on Cl^- transport by rat submandibular acini. *J. Dent. Res.* 67:561-564.
- Ambudkar, I., J. E. Melvin, and B. J. Baum. 1988. $\alpha 1$ -Adrenergic regulation of Cl^- and Ca^{2+} movements in rat parotid acinar cells. *Pfluegers Arch. Eur. J. Physiol.* 412:75-79.
- Martinez, J. R., N. Cassity, and P. Reed. 1988. Effects of isoproterenol on Cl^- transport in rat submandibular salivary gland acini. *Arch. Oral Biol.* 33:505-509.
- Kinne, R., E. Kinne-Saffran, H. Schutz, and B. Scholermann. 1986. Ammonium transport in medullary thick ascending limb of rabbit kidney: involvement of the $\text{Na}^+/\text{K}^+/\text{Cl}^-$ cotransporter. *J. Membr. Biol.* 94:279-284.
- Kinne, R., B. Koenig, J. Hannafin, E. Kinne-Saffran, D. M. Scott, and K. Zierold. 1985. The use of membrane vesicles to study the NaCl/KCl cotransporter involved in active transepithelial chloride transport. *Pfluegers Arch. Eur. J. Physiol.* 405:S101-S105.
- Knepper, M. A., R. Packer, and D. W. Good. 1989. Ammonium transport in the kidney. *Physiol. Rev.* 69:179-249.
- Sreebny, L. M., and S. S. Schwartz. 1986. A reference guide to drugs and dry mouth. *Gerodontology*. 5:75-99.
1990. The Physician's Desk Reference. E. R. Barnhart, Oradell, N.J.
- Star, R. A., M. B. Burg, and M. A. Knepper. 1985. Bicarbonate secretion and chloride absorption by rabbit cortical collecting ducts. Role of chloride/bicarbonate exchange. *J. Clin. Invest.* 76:1123-1130.
- Melvin, J. E., A. Moran, and R. J. Turner. 1988. The role of HCO_3^- and Na^+/H^+ exchange in the response of rat parotid acinar cells to muscarinic stimulation. *J. Biol. Chem.* 263:19564-19569.
- Roos, A., and W. F. Boron. 1981. Intracellular pH. *Physiol. Rev.* 61:296-434.
- Ito, H., B. J. Baum, and G. S. Roth. 1981. α -adrenergic regulation of rat parotid gland exocrine protein secretion during aging. *Mech. Ageing Dev.* 15:177-188.
- Carlsöö, B., A. Danielsson, R. Henriksson, and L. Idahl. 1981. Characterization of the rat parotid beta-adrenoceptor. *Br. J. Pharmacol.* 72:271-276.
- Dreux, C., V. Imhoff, C. Huleux, S. Busson, and B. Rossignol. 1986. Forskolin, a tool for rat parotid secretion studies: ^{45}Ca efflux is not related to cAMP. *Am. J. Physiol.* 251:C754-C762.
- Butcher, F. R., and J. W. Putney. 1980. Regulation of parotid gland function by cyclic nucleotides and calcium. In *Advances in Cyclic Nucleotide Research*. P. Greengard, and G. A. Robison, editors. Raven Press, New York. 13:215-249.
- Takemura, H. 1985. Changes in cytosolic free calcium concentration in isolated rat parotid cells by cholinergic and beta-adrenergic agonists. *Biochem. Biophys. Res. Commun.* 131:1048-1055.
- Horn, V. J., B. J. Baum, and I. S. Ambudkar. 1988. Beta-adrenergic receptor stimulation induces inositol trisphosphate production and Ca^{2+} mobilization in rat parotid acinar cells. *J. Biol. Chem.* 263:12454-12460.
- Hughes, A. R., H. Takemura, and J. W. Putney. 1989. Does beta-adrenoceptor activation stimulate Ca^{2+} mobilization and inositol trisphosphate formation in parotid acinar cells? *Cell Calcium*. 10:519-525.
- Minneman, K. P., A. Hedberg, and P. B. Molinoff. 1979. Comparison of beta adrenergic receptor subtypes in mammalian tissues. *J. Pharmacol. Exp. Ther.* 211:502-508.
- Fuller, C. M., and D. V. Gallacher. 1984. Beta-adrenergic receptor mechanisms in rat parotid glands: activation by nerve stimulation and 3-isobutyl-1-methylxanthine. *J. Physiol. (Lond.)* 356:335-348.
- Spearman, T. N., and F. R. Butcher. 1989. Cellular regulation of amylase secretion by the parotid gland. *Handb. Physiol.* 3:63-77.
- Lands, A. M., A. Arnold, J. P. McAuliff, F. P. Luduena, and T. G. Brown. 1967. Differentiation of receptor systems activated by sympathomimetic amines. *Nature (Lond.)* 214:597-598.
- Case, R. M., A. D. Conigrave, I. Novak, and J. A. Young. 1980. Electrolyte and protein secretion by the perfused rabbit mandibular gland stimulated with acetylcholine or catecholamines. *J. Physiol. (Lond.)* 300:467-487.
- Pewitt, E. B., R. S. Hegde, M. Haas, and H. C. Palfrey. 1990. The regulation of $\text{Na}/\text{K}/\text{Cl}$ cotransport and bumetanide binding in avian erythrocytes by protein phosphorylation and dephosphorylation. *J. Biol. Chem.* 265:20747-20756.
- Larsson, O., and L. Olgart. 1989. The enhancement of carbachol-induced salivary secretion by VIP and CGRP in rat parotid is mimicked by forskolin. *Acta Physiol. Scand.* 137:231-236.
- Fox, P. C., J. C. Atkinson, A. A. Macynski, A. Wolff, D. S. Kung, I. H. Valdez, W. Jackson, R. A. Delapenha, J. Shiroky, and B. J. Baum. 1991. Pilocarpine treatment of salivary gland hypofunction and dry mouth (xerostomia). *Arch. Intern. Med.* 151:1149-1152.